🚀 VC round data is live in beta, check it out!
Outlook Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Outlook Therapeutics and similar public comparables like Initiator Pharma, Skye Bioscience, Gensight Biologics, Tevogen Bio and more.
Outlook Therapeutics Overview
About Outlook Therapeutics
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Founded
2010
HQ
Employees
17
Website
Sectors
Financials (LTM)
EV
$52M
Outlook Therapeutics Financials
Outlook Therapeutics reported last 12-month revenue of $12M.
In the same LTM period, Outlook Therapeutics generated $8M in gross profit and had net loss of ($55M).
Revenue (LTM)
Outlook Therapeutics P&L
In the most recent fiscal year, Outlook Therapeutics reported revenue of $1M and EBITDA of ($64M).
Outlook Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $12M | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | $8M | XXX | $57K | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 4% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($64M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (4498%) | XXX | XXX | XXX |
| EBIT Margin | (416%) | XXX | (4362%) | XXX | XXX | XXX |
| Net Profit | ($55M) | XXX | ($62M) | XXX | XXX | XXX |
| Net Margin | (463%) | XXX | (4416%) | XXX | XXX | XXX |
| Net Debt | — | — | $22M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Outlook Therapeutics Stock Performance
Outlook Therapeutics has current market cap of $24M, and enterprise value of $52M.
Market Cap Evolution
Outlook Therapeutics' stock price is $0.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52M | $24M | -6.5% | XXX | XXX | XXX | $-0.60 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOutlook Therapeutics Valuation Multiples
Outlook Therapeutics trades at 4.4x EV/Revenue multiple, and (0.8x) EV/EBITDA.
EV / Revenue (LTM)
Outlook Therapeutics Financial Valuation Multiples
As of April 11, 2026, Outlook Therapeutics has market cap of $24M and EV of $52M.
Equity research analysts estimate Outlook Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Outlook Therapeutics has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $24M | XXX | $24M | XXX | XXX | XXX |
| EV (current) | $52M | XXX | $52M | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | 36.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.8x) | XXX | XXX | XXX |
| EV/EBIT | (1.1x) | XXX | (0.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | 907.3x | XXX | XXX | XXX |
| P/E | (0.4x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Outlook Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Outlook Therapeutics Margins & Growth Rates
Outlook Therapeutics' revenue in the last 12 month grew by 243%.
Outlook Therapeutics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $3.9M for the same period.
Outlook Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 243% | XXX | 1401% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (4498%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (9%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 399% | XXX | 2825% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 143% | XXX | 1923% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 4748% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Outlook Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Initiator Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Skye Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Gensight Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tevogen Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Arterra Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Outlook Therapeutics M&A Activity
Outlook Therapeutics acquired XXX companies to date.
Last acquisition by Outlook Therapeutics was on XXXXXXXX, XXXXX. Outlook Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Outlook Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOutlook Therapeutics Investment Activity
Outlook Therapeutics invested in XXX companies to date.
Outlook Therapeutics made its latest investment on XXXXXXXX, XXXXX. Outlook Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Outlook Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Outlook Therapeutics
| When was Outlook Therapeutics founded? | Outlook Therapeutics was founded in 2010. |
| Where is Outlook Therapeutics headquartered? | Outlook Therapeutics is headquartered in United States. |
| How many employees does Outlook Therapeutics have? | As of today, Outlook Therapeutics has over 17 employees. |
| Who is the CEO of Outlook Therapeutics? | Outlook Therapeutics' CEO is Robert Charles Jahr. |
| Is Outlook Therapeutics publicly listed? | Yes, Outlook Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Outlook Therapeutics? | Outlook Therapeutics trades under OTLK ticker. |
| When did Outlook Therapeutics go public? | Outlook Therapeutics went public in 2016. |
| Who are competitors of Outlook Therapeutics? | Outlook Therapeutics main competitors are Initiator Pharma, Skye Bioscience, Gensight Biologics, Tevogen Bio. |
| What is the current market cap of Outlook Therapeutics? | Outlook Therapeutics' current market cap is $24M. |
| What is the current revenue of Outlook Therapeutics? | Outlook Therapeutics' last 12 months revenue is $12M. |
| What is the current revenue growth of Outlook Therapeutics? | Outlook Therapeutics revenue growth (NTM/LTM) is 243%. |
| What is the current EV/Revenue multiple of Outlook Therapeutics? | Current revenue multiple of Outlook Therapeutics is 4.4x. |
| Is Outlook Therapeutics profitable? | No, Outlook Therapeutics is not profitable. |
| What is the current net income of Outlook Therapeutics? | Outlook Therapeutics' last 12 months net income is ($55M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.